As one of the most significant epidemics in the world, human obesity is strongly associated with several diseases such as hypertension, type 2 diabetes mellitus, stroke, coronary artery diseases and certain types of cancer, thus representing a significant risk of morbidity and mortality [1] . During the past decade or so, mouse and human genetic studies together with detailed pharmacological investigations revealed that the leptin-regulated pathway plays a critical role in regulating food intake and energy expenditure. Mutations in seven genes including leptin (LEP) [2] , leptin receptor (LEPR) [3] , prohormone convertase 1 (PC1) [4], [5], [6, 7], [8, 9] and single-minded homolog 1 (SIM1) [10] , cause monogenic obesity in human. Of these genes, the MC4R has been identified as a key component in the leptin-regulated pathway [11] [12] [13] [14] . Mutations in the MC4R represent the most common monogenic form of human obesity [15] [16] [17] , with up to 6% of the early-onset severe obesity caused by MC4R mutations in some populations [15] . 
nonsense and missense mutations. Many mutant MC4Rs has been functionally characterized in detail (reviewed in [17, 20] ). Previously, several groups reported the identification of 10 novel MC4R mutants in obese children or adults of diverse ethnic groups. They are R7C [21] in the N-terminus, C84R [22] in TM2, S127L [23] and S136F [24] in TM3, W174C [25] in TM4, A219V [26] and P230L [23] in IL3, F261S [27] in TM6, I317V [25] and L325F [26] in the C terminal tail (Fig. 1) . The clinical characteristics of the patients carrying these MC4R mutations are listed in Table 1 . The functional properties of these mutants were either not investigated or only partially determined. In this study, we set to quantitatively measure both the cell surface and total expression levels of these mutants, and to analyse their functional properties including ligand binding and signalling properties.
Bouvier and colleagues pioneered the field of using small molecule antagonists as pharmacological chaperones for GPCRs [28] . These molecules act as folding templates, assisting the mutants to fold into conformations that allow their exit from the endoplasmic reticulum. Since then, pharmacological chaperones have been identified for naturally occurring mutations in rhodopsin and gonadotropin-releasing hormone receptor (GnRHR) [29] [30] [31] [32] and wild-type (WT) or laboratory-generated mutants in several other GPCRs [33] [34] [35] [36] [37] [38] [39] . The [32] . Recently, it has been shown that treatment of patients with nephrogenic diabetes insipidus harbouring transport-defective V2 vasopressin receptor mutations with the non-peptide antagonist SR49059 decreased urine volume and water intake [40] [41] , was shown to be a MC4R inverse agonist [42] .
, proving the clinical utility of pharmacological chaperones. Because the majority of the naturally occurring MC4R mutants are retained intracellularly, we tested the potential chaperone activity of a small molecule MC4R antagonist, ML00253764. This compound, [2-{2-[2-(5-bromo-2-methoxyphenyl)-ethyl]-3-fluorophenyl}-4,5-dihydro-1H-imidazolium hydrochloride], originally discovered by Vos and colleagues

Materials and methods
Cells, plasmids and peptides
Human embryonic kidney (HEK) 293 and 293T cells (American Type
Culture Collection, Manassas, VA, USA) were incubated at 5% CO2 in This assay was performed as described before [46] . 
NDP-MSH stimulation of intracellular cAMP generation
Statistical analyses
Data were presented as mean Ϯ S.E.M. Statistical analyses were performed with Prism 4. For comparisons on cell surface and total expression of the WT and mutant hMC4Rs and cell surface maximal binding and
Fig. 2 Cell surface (A) and total (B) expressions of WT and mutant hMC4Rs stably expressed in HEK293 cells. Establishment of the stable cell lines was performed as described in 'Materials and methods'. Cell surface and total expression levels of the WT and mutant hMC4Rs were quantitatively determined by flow cytometry. The results are expressed as percentage of total or cell surface expression levels of the WT hMC4R. Shown are mean Ϯ S.E.M. of three experiments. Star (ଙ) indicates significant difference from WT hMC4R (P Ͻ 0.05). maximal signalling, one-sample unpaired t-test was used. For comparisons of IC50 and EC50, a two-sample unpaired t-test was used.
Differences with a P Ͻ 0.05 were considered statistically significant.
Results
Cell surface and total expression levels of the mutant hMC4Rs
Previous 
Ligand binding properties of the mutant hMC4Rs
We further investigated the ligand binding properties of the WT and mutant hMC4Rs using whole-cell binding assays in HEK293T (Fig. 4 and Table 2 ). Previous studies suggested that loss of basal signalling might be one defect of the receptor in MC4R mutants identified from obese patients [47] . Therefore, we also determined the constitutive activities of the mutants in this study. As shown in Fig. 5 , when compared with the WT hMC4R, S127L and P230L had significantly increased constitutive activities, whereas W174C and A219V had significantly decreased constitutive activities. The other six mutants had similar constitutive activities as the WT hMC4R (Fig. 5) . 
Fig. 3 NDP-MSH binding assay of the WT and mutant hMC4Rs transiently expressed in HEK293T cells. HEK293T cells were transiently transfected with the indicated hMC4R constructs and binding assays were performed as described in 'Materials and methods'. Different concentrations of unlabeled NDP-MSH (A) or
Amino acid requirement at codon 136 of the hMC4R for receptor function
Significantly different from WT hMC4R, P Ͻ 0.001. Data shown are the mean Ϯ S.E.M. of the number of experiments indicated. The Rmax of WT hMC4R was 948 Ϯ 86 pmol cAMP/10 6 cells (mean Ϯ S.E.M. of nine experiments). IC50 is the concentration of NDP-MSH that is needed to cause 50% inhibition in the binding assay. EC50 is the concentration of NDP-MSH that results in 50% stimulation of the maximal response.
binding and signalling properties of the mutants were measured. As shown in Fig. 6A and Table 3 , all seven mutants had normal Bmax compared to the WT hMC4R (S136D even had a small but significant increase in Bmax). Except for S136R and S136T that had significantly higher IC50s, the other five mutants had similar IC50s as the WT hMC4R. All mutants can signal in response to NDP-MSH stimulation. S136L had a small but significant increase in Rmax. However, the maximal responses were decreased in S136A, S136C and S136R mutants (Fig. 6B and Table 3 ). Four mutants, including S136A, S136L, S136R and S136Y, had significantly increased EC50s compared to the WT MC4R, whereas S136C, S136D and S136T had normal EC50s (Table 3) . [21] . We observed a similar but statistically significant decrease in maximal response (Fig. 4 and Table 2 ). Its total expression was decreased; therefore, a class I mutant. S127L, was identified independently in several studies [23, 50, 51] . Previous reports showed that S127L is normal in cell surface expression [23, 50] whereas its cAMP response is impaired with decreased Rmax and increased EC50 upon stimulation by either ␣-MSH [23, 50, 51] , ␤-MSH [51] or ␥1-MSH [51] . In our experiments, S127L had a significantly decreased Rmax with normal EC50. Importantly, although it had normal total expression, S127L had decreased cell surface expression compared to the WT hMC4R. Thus, S127L is a class II mutant. W174C and I317V hMC4Rs were identified from severely obese Italian adults and were not functionally characterized [25] . We showed that W174C had a significantly decreased total expression compared to the WT hMC4R and undetectable cell surface expression (Fig. 2) . No ligand binding and cAMP response could be detected (Figs 3 and  4) . In contrast, the cell surface expression, ligand binding and cAMP response of I317V are similar to the WT hMC4R. Its total expression is even higher than that of the WT hMC4R. Therefore, I317V might represent a rare polymorphism with no overt functional defect. [23] . We confirmed that P230L is constitutively active. We further showed that P230L had significantly decreased cell surface expression, with a corresponding decrease in Bmax. Its total expression was normal. Therefore, P230L is defective in intracellular trafficking and a class II mutant. F261S was identified from obese Chinese and preliminary characterization showed that it has decreased Rmax and increased IC50 [27] . Intracellular retention of the mutant receptor was recently reported [52] . Our data are consistent with these observations. Furthermore, we showed that the cell surface expression of F261S was significantly decreased to 35% of that of the WT hMC4R, although the total expression is similar to the WT hMC4R. Corresponding decreases in Bmax and Rmax were observed whereas the IC50 and EC50 were not significantly altered. Thus, F261S is also defective in intracellular trafficking, hence a class II mutant. Mutants A219V and L325F were identified from German patients [26] . Using NDP-MSH as the ligand, we showed that A219V had significantly decreased maximal binding, although its cell surface and total expression levels were similar to the WT hMC4R (Fig. 2) [26] . Mutant S136F was reported as a loss-of-function mutant with normal cell surface expression [24] . Our data are consistent with these observations. We further showed that total expression and ligand binding properties of S136F were also normal compared to the WT hMC4R. Therefore, S136F is a class IV mutant. A recent study reported similar data [53] . Multiple mutagenesis experiments showed that S136 is important for signalling. Mutations into alanine, cysteine and arginine, resulted in decreased maximal response, whereas mutations into cysteine, leucine, arginine and tyrosine, resulted in increased EC50s (Fig. 6 and Table 3 ). Tan and colleagues showed that mutation of S136 into proline resulted in decreased cell surface expression, with corresponding decreases in Bmax and Rmax [53] .
Functional rescue of C84R and W174C hMC4Rs
Functional studies of Hinney and colleagues showed that P230L is a constitutively active mutant with increased Rmax and decreased EC50 upon stimulation by ␣-MSH
Vaisse and colleagues suggested that loss of constitutive activity might be one cause of obesity in MC4R mutation carriers [47] . In the current study, we measured the constitutive activities of the [17, 20] (Fig. 7A and B) . We then tested the functions of the rescued mutants. Both mutants had robust signalling, amounting to 80% of the signalling elicited by WT hMC4R treated with vehicle (Fig. 7C) [57] ). This is not uncommon. It is well known that the maturation of GPCR is rate limiting in many receptors (reviewed in [58] 
